Interaction between the HTLV-1 envelope and cellular proteins: Impact on virus infection and restriction

Future Medicinal Chemistry

Volumn 2, Issue 11, 2010, Pages 1651-1668

  Ilinskaya, Anna ^a   Heidecker, Gisela ^a   Jones, Kathryn ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 2; GLUCOSE TRANSPORTER 3; GLUCOSE TRANSPORTER 4; NEUROPILIN 1; PROTEOHEPARAN SULFATE; TYROSINE; VIRUS ENVELOPE PROTEIN;

CARBOXY TERMINAL SEQUENCE; CELL MIGRATION; DENDRITIC CELL; HUMAN T CELL LEUKEMIA VIRUS; HUMAN T LYMPHOTROPIC VIRUS 1; INTERNALIZATION; NONHUMAN; PDZ DOMAIN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; VIRION; VIROGENESIS; VIRUS ASSEMBLY; VIRUS ENVELOPE; VIRUS INFECTION;

AMINO ACID SEQUENCE; CELL ADHESION MOLECULES; GLUCOSE TRANSPORTER TYPE 1; HEPARAN SULFATE PROTEOGLYCANS; HTLV-I INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; LECTINS, C-TYPE; MOLECULAR SEQUENCE DATA; NEUROPILIN-1; RECEPTORS, CELL SURFACE; RECEPTORS, VIRUS; VIRAL ENVELOPE PROTEINS;

EID: 78649233723     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.255     Document Type: Review

References (163)

1. Matsuoka M. Human T-cell leukemia virus type I and adult T-cell leukemia. Oncogene 22(33), 5131-5140 (2003). (Pubitemid 37059594)
2. Faris M. Potential for molecular targeted therapy for adult T-cell leukemia/lymphoma. Int. Rev. Immunol. 27(1-2), 71-78 (2008).
3. Taylor Gp, Matsuoka M. Natural history of adult T-cell leukemia/lymphoma and approaches to therapy. Oncogene 24(39), 6047-6057 (2005).
4. Matsuoka M, Jeang KT. Human T-cell leukemia virus type I at age 25: a progress report. Cancer Res. 65(11), 4467-4470 (2005).
5. Takatsuki K. Discovery of adult T-cell leukemia. Retrovirology 2, 16 (2005).
6. Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 50(3), 481-492 (1977).
7. Uchiyama T: Human T-cell leukemia virus type I (HTLV-I) and human diseases. Ann. Rev. Immunol. 15, 15-37 (1997).
8. Manns A, Hisada M, La Grenade L. Human T-lymphotropic virus type I infection. Lancet 353(9168), 1951-1958 (1999).
9. Bangham CR. HTLV-1 infections. J. Clin. Pathol. 53(8), 581-586 (2000).
10. Richardson JH, Edwards AJ, Cruickshank JK, Rudge P, Dalgleish AG. In vivo cellular tropism of human T-cell leukemia virus type 1. J. Virol. 64(11), 5682-5687 (1990). (Pubitemid 20364571)
11. Igakura T, Stinchcombe JC, Goon PK et al. Spread of HTLV-1 between lymphocytes by virus-induced polarization of the cytoskeleton. Science (NY) 299(5613), 1713-1716 (2003).
12. Nejmeddine M, Bangham CRM. The HTLV-1 virological synapse. Viruses 2(7), 1427-1447 (2010).
13. Sattentau Q. Avoiding the void: cell-to-cell spread of human viruses. Nat. Rev. Microbiol. 6(11), 815-826 (2008).
14. Mothes W, Sherer NM, Jin J, Zhong P. Virus cell-to-cell transmission. J. Virol. 84(17), 8360-8368 (2010).
15. Nejmeddine M, Negi VS, Mukherjee S et al. HTLV-1-tax and ICAM-1 act on T-cell signal pathways to polarize the microtubule-organizing center at the virological synapse. Blood 114(5), 1016-1025 (2009).
16. Sherer NM, Mothes W. Cytonemes and tunneling nanotubules in cell-cell communication and viral pathogenesis. Trends Cell biol. 18(9), 414-420 (2008).
17. Jin J, Sherer NM, Heidecker G, Derse D, Mothes W. Assembly of the murine leukemia virus is directed towards sites of cell-cell contact. PLoS Biol. 7(7), e1000163 (2009).
18. Sherer NM, Lehmann MJ, Jimenez-Soto LF, Horensavitz C, Pypaert M, Mothes W. Retroviruses can establish flopodial bridges for effcient cell-to-cell transmission. Nat. Cell Biol. 9(3), 310-315 (2007).
19. Pais-Correia AM, Sachse M, Guadagnini S et al. Bioflm-like extracellular viral assemblies mediate HTLV-1 cell-to-cell transmission at virological synapses. Nat. Med. 16(1), 83-89 (2009).
20. Jones KS, Green PL. Cloaked virus slips between cells. Nat. Med. 16(1), 25-27 (2010).
21. + T-cells. Nat. Med. 14(4), 429-436 (2008).
22. Manel N, Taylor N, Kinet S et al. HTLV envelopes and their receptor GLUT1, the ubiquitous glucose transporter: a new vision on HTLV infection? Front. Biosci. 9, 3218-3241 (2004).
23. Byland R, Marsh M. Traffcking of viral membrane proteins. Curr. Top. Microbiol. Immunol. 285, 219-254 (2005).
24. Hunter E, Swanstrom R. Retrovirus envelope glycoproteins. Curr. Top. Microbiol. Immunol. 157, 187-253 (1990).
25. Manel N, Battini Jl, Taylor N, Sitbon M. HTLV-1 tropism and envelope receptor. Oncogene 24(39), 6016-6025 (2005).
26. Rosenberg AR, Delamarre L, Pique C, Le Blanc I, Griffth G, Dokhelar MC. Early assembly step of a retroviral envelope glycoprotein: analysis using a dominant negative assay. J. Cell Biol. 145(1), 57-68 (1999).
27. Pique C, Tursz T, Dokhelar MC. Mutations introduced along the HTLV-I envelope gene result in a nonfunctional protein: a basis for envelope conservation? EMBO J. 9(13), 4243-4248 (1990).
28. Hattori S, Kiyokawa T, Imagawa K et al. Identifcation of gag and env gene products of human T-cell leukemia virus (HTLV). Virology 136(2), 338-347 (1984).
29. Schneider J, Yamamoto N, Hinuma Y, Hunsmann G. Precursor polypeptides of adult T-cell leukaemia virus. Detection with antisera against isolated polypeptides gp68, p24 and p19. J. Gen. Virol. 65 (12), 2249-2258 (1984).
30. Delamarre L, Rosenberg AR, Pique C, Pham D, Callebaut I, Dokhelar MC. The HTLV-1 envelope glycoproteins: structure and functions. J. Acquir. Immune Defc. Syndr. Hum. Retrovirol. 13(Suppl. 1), S85-S91 (1996).
31. Paine E, Gu R, Ratner L. Structure and expression of the human T-cell leukemia virus type 1 envelope protein. Virology 199(2), 331-338 (1994). (Pubitemid 24168971)
32. Pique C, Pham D, Tursz T, Dokhelar MC. Human T-cell leukemia virus type I envelope protein maturation process: requirements for syncytium formation. J. Virol. 66(2), 906-913 (1992).
33. Gallaher WR, Ball JM, Garry RF, Martin-Amedee AM, Montelaro RC. A general model for the surface glycoproteins of HIV and other retroviruses. AIDS Res. Hum. Retro. 11(2), 191-202 (1995).
34. Delamarre L, Pique C, Pham D, Tursz T, Dokhelar MC. Identifcation of functional regions in the human T-cell leukemia virus type I SU glycoprotein. J. Virol. 68(6), 3544-3549 (1994).
35. Delamarre L, Rosenberg AR, Pique C, Pham D, Dokhelar MC. A novel human T-leukemia virus type 1 cell-to-cell transmission assay permits defnition of SU glycoprotein amino acids important for infectivity. J. Virol. 71(1), 259-266 (1997).
36. Rosenberg AR, Delamarre L, Preira A, Dokhelar MC. Analysis of functional conservation in the surface and transmembrane glycoprotein subunits of human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2. J. Virol. 72(9), 7609-7614 (1998).
37. Tsukahara T, Wielgosz MM, Ratner L. Characterization of envelope glycoprotein mutants for human T-cell leukemia virus type 1 infectivity and immortalization. J. Virol. 75(19), 9553-9559 (2001).
38. Lambert S, Bouttier M, Vassy R et al. HTLV-1 uses HSPG and neuropilin-1 for entry by molecular mimicry of vegf165. Blood 113(21), 5176-5185 (2009).
39. Manel N, Kim FJ, Kinet S, Taylor N, Sitbon M, Battini JL. The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV. Cell 115(4), 449-459 (2003).
40. Kim FJ, Manel N, Garrido EN, Valle C, Sitbon M, Battini JL. HTLV-1 and -2 envelope SU subdomains and critical determinants in receptor binding. Retrovirology 1, 41 (2004).
41. Kim FJ, Seiliez I, Denesvre C, Lavillette D, Cosset Fl, Sitbon M. Defnition of an amino-terminal domain of the human T-cell leukemia virus type 1 envelope surface unit that extends the fusogenic range of an ecotropic murine leukemia virus. J. Biol. Chem. 275(31), 23417-23420 (2000).
42. Jones KS, Fugo K, Petrow-Sadowski C et al. Human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2 use different receptor complexes to enter T-cells. J. Virol. 80(17), 8291-8302 (2006).
43. Rey MA, Prasad R, Tailor CS. The c domain in the surface envelope glycoprotein of subgroup c feline leukemia virus is a second receptor-binding domain. Virology 370(2), 273-284 (2008).
44. Johnston ER, Albritton LM, Radke K. Envelope proteins containing single amino acid substitutions support a structural model of the receptor-binding domain of bovine leukemia virus surface protein. J. Virol. 76(21), 10861-10872 (2002).
45. Li K, Zhang S, Kronqvist M et al. Intersubunit disulfde isomerization controls membrane fusion of human T-cell leukemia virus env. J. Virol. 82(14), 7135-7143 (2008).
46. Barnett AL, Cunningham JM. Receptor binding transforms the surface subunit of the mammalian c-type retrovirus envelope protein from an inhibitor to an activator of fusion. J. Virol. 75(19), 9096-9105 (2001).
47. Barnett AL, Davey RA, Cunningham JM. Modular organization of the friend murine leukemia virus envelope protein underlies the mechanism of infection. Proc. Natl Acad. Sci. USA 98(7), 4113-4118 (2001).
48. Lavillette D, Boson B, Russell SJ, Cosset FL. Activation of membrane fusion by murine leukemia viruses is controlled in cis or in trans by interactions between the receptor-binding domain and a conserved disulfde loop of the carboxy terminus of the surface glycoprotein. J. Virol. 75(8), 3685-3695 (2001).
49. Lavillette D, Maurice M, Roche C, Russell SJ, Sitbon M, Cosset FL. A proline-rich motif downstream of the receptor binding domain modulates conformation and fusogenicity of murine retroviral envelopes. J. Virol. 72(12), 9955-9965 (1998).
50. Wallin M, Ekstrom M, Garoff H. The fusion-controlling disulfde bond isomerase in retrovirus env is triggered by protein destabilization. J. Virol. 79(3), 1678-1685 (2005).
51. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type c retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc. Natl Acad. Sci. USA 77(12), 7415-7419 (1980).
52. Hoxie JA, Matthews DM, Cines DB. Infection of human endothelial cells by human T-cell leukemia virus type I. Proc. Natl Acad. Sci. USA 81(23), 7591-7595 (1984).
53. Clapham P, Nagy K, Cheingsong-Popov R, Exley M, Weiss RA. Productive infection and cell-free transmission of human T-cell leukemia virus in a nonlymphoid cell line. Science (NY) 222(4628), 1125-1127 (1983).
54. Ho DD, Rota TR, Hirsch MS. Infection of human endothelial cells by human T-lymphotropic virus type I. Proc. Natl Acad. Sci. USA 81(23), 7588-7590 (1984).
55. Fujino T, Fujiyoshi T, Yashiki S, Sonoda S, Otsuka H, Nagata Y. HTLV-I transmission from mother to fetus via placenta. Lancet 340(8828), 1157 (1992).
56. Clarke MF, Gelmann EP, Reitz MS Jr. Homology of human T-cell leukaemia virus envelope gene with class I HLA gene. Nature 305(5929), 60-62 (1983).
57. Kohtz DS, Altman A, Kohtz JD, Puszkin S. Immunological and structural homology between human T-cell leukemia virus type I envelope glycoprotein and a region of human interleukin-2 implicated in binding the b receptor. J. Virol. 62(2), 659-662 (1988).
58. Imai T, Fukudome K, Takagi S et al. C33 antigen recognized by monoclonal antibodies inhibitory to human T cell leukemia virus type 1-induced syncytium formation is a member of a new family of transmembrane proteins including cd9, cd37, cd53 and cd63. J. Immunol. 149(9), 2879-2886 (1992).
59. Fukudome K, Furuse M, Imai T et al. Identifcation of membrane antigen c33 recognized by monoclonal antibodies inhibitory to human T-cell leukemia virus type 1 (HTLV-1)-induced syncytium formation: altered glycosylation of c33 antigen in htlv-1-positive t cells. J. Virol. 66(3), 1394-1401 (1992).
60. Sagara Y, Ishida C, Inoue Y, Shiraki H, Maeda Y. 71-kilodalton heat shock cognate protein acts as a cellular receptor for syncytium formation induced by human T-cell lymphotropic virus type 1. J. Virol. 72(1), 535-541 (1998).
61. Mueckler M, Caruso C, Baldwin SA et al. Sequence and structure of a human glucose transporter. Science (NY) 229(4717), 941-945 (1985).
62. Scheepers A, Joost HG, Schurmann A. The glucose transporter families SGLT and GLUT: molecular basis of normal and aberrant function. Jpen. 28(5), 364-371 (2004).
63. Jones KS, Akel S, Petrow-Sadowski C, Huang Y, Bertolette DC, Ruscetti F W. Induction of human T-cell leukemia virus type I receptors on quiescent naive T-lymphocytes by TGF-b. J. Immunol. 174(7), 4262-4270 (2005).
64. Chakrabarti R, Jung CY, Lee TP, Liu H, Mookerjee BK. Changes in glucose transport and transporter isoforms during the activation of human peripheral blood lymphocytes by phytohemagglutinin. J. Immunol. 152(6), 2660-2668 (1994).
65. Kinet S, Swainson L, Lavanya M et al. Isolated receptor binding domains of HTLV-1 and HTLV-2 envelopes bind GLUT-1 on activated CD4+ and CD8+ T cells. Retrovirology 4, 31 (2007).
66. Nath MD, Ruscetti F W, Petrow-Sadowski C, Jones KS. Regulation of the cell-surface expression of an HTLV-I binding protein in human T cells during immune activation. Blood 101(8), 3085-3092 (2003).
67. Coskun AK, Sutton RE. Expression of glucose transporter 1 confers susceptibility to human T-cell leukemia virus envelope-mediated fusion. J. Virol. 79(7), 4150-4158 (2005).
68. Kim JW, Closs EI, Albritton LM, Cunningham JM. Transport of cationic amino acids by the mouse ecotropic retrovirus receptor. Nature 352(6337), 725-728 (1991).
69. Tailor CS, Lavillette D, Marin M, Kabat D. Cell surface receptors for gammaretroviruses. Curr. Tops. Microbiol. Immunol. 281, 29-106 (2003).
70. Overbaugh J, Miller AD, Eiden MV. Receptors and entry cofactors for retroviruses include single and multiple transmembrane-spanning proteins as well as newly described glycophosphatidylinositol-anchored and secreted proteins. Microbiol. Mol. Biol. Rev. 65(3), 371-389 (2001).
71. Manel N, Battini JL, Sitbon M. Human T cell leukemia virus envelope binding and virus entry are mediated by distinct domains of the glucose transporter glut1. J. Biol. Chem. 280(32), 29025-29029 (2005).
72. Takenouchi N, Jones KS, Lisinski I et al. Glut1 is not the primary binding receptor but is associated with cell-to-cell transmission of human T-cell leukemia virus type 1. J. Virol. 81(3), 1506-1510 (2007).
73. Ghez D, Lepelletier Y, Lambert S et al. Neuropilin-1 is involved in human T-cell lymphotropic virus type 1 entry. J. Virol. 80(14), 6844-6854 (2006).
74. Tordjman R, Lepelletier Y, Lemarchandel V et al. A neuronal receptor, neuropilin-1, is essential for the initiation of the primary immune response. Nat. Immunol. 3(5), 477-482 (2002).
75. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specifc receptor for vascular endothelial growth factor. Cell 92(6), 735-745 (1998).
76. Miao HQ, Lee P, Lin H, Soker S, Klagsbrun M. Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression. FASEB J. 14(15), 2532-2539 (2000).
77. Bagri A, Tessier-Lavigne M, Watts RJ. Neuropilins in tumor biology. Clin. Cancer Res. 15(6), 1860-1864 (2009).
78. He Z, Tessier-Lavigne M. Neuropilin is a receptor for the axonal chemorepellent semaphorin III. Cell 90(4), 739-751 (1997).
79. Guttmann-Raviv N, Kessler O, Shraga-Heled N, Lange T, Herzog Y, Neufeld G. The neuropilins and their role in tumorigenesis and tumor progression. Cancer letters 231(1), 1-11 (2006). (Pubitemid 41779447)
80. Nakamura F, Goshima Y. Structural and functional relation of neuropilins. Adv. Exp. Med. Biol. 515, 55-69 (2002).
81. Jin Q, Alkhatib B, Cornetta K, Alkhatib G. Alternate receptor usage of neuropilin-1 and glucose transporter protein 1 by the human T cell leukemia virus type 1. Virology 396(2), 203-212 (2010).
82. Jin Q, Agrawal L, Vanhorn-Ali Z, Alkhatib G. GLUT-1-independent infection of the glioblastoma/astroglioma u87 cells by the human T cell leukemia virus type 1. Virology 353(1), 99-110 (2006).
83. Pinon JD, Klasse PJ, Jassal SR et al. Human T-cell leukemia virus type 1 envelope glycoprotein gp46 interacts with cell surface heparan sulfate proteoglycans. J. Virol. 77(18), 9922-9930 (2003).
84. Okuma K, Dalton KP, Buonocore L, Ramsburg E, Rose JK. Development of a novel surrogate virus for human T-cell leukemia virus type 1: inhibition of infection by osteoprotegerin. J. Virol. 77(15), 8562-8569 (2003).
85. Bernfeld M, Gotte M, Park PW et al. Functions of cell surface heparan sulfate proteoglycans. Ann. Rev. Biochem. 68, 729-777 (1999).
86. Spillmann D. Heparan sulfate: ANCHOR for viral intruders? Biochimie 83(8), 811-817 (2001).
87. + T cells. J. Virol. 79(20), 12692-12702 (2005).
88. Geretti E, Shimizu A, Klagsbrun M. Neuropilin structure governs VEGF and semaphorin binding and regulates angiogenesis. Angiogenesis 11(1), 31-39 (2008).
89. Vander Kooi C W, Jusino MA, Perman B, Neau DB, Bellamy HD, Leahy DJ Structural basis for ligand and heparin binding to neuropilin b domains. Proc. Natl Acad. Sci. USA 104(15), 6152-6157 (2007).
90. Lavanya M, Kinet S, Montel-Hagen A et al. Cell surface expression of the bovine leukemia virus-binding receptor on B and T lymphocytes is induced by receptor engagement. J. Immunol . 181(2), 891-898 (2008).
91. Jones KS, Huang YK, Chevalier SA et al. The receptor complex associated with human T-cell lymphotropic virus type 3 (HTLV-3) env-mediated binding and entry is distinct from, but overlaps with, the receptor complexes of HTLV-1 and HTLV-2. J. Virol. 83(10), 5244-5255 (2009).
92. Sommerfelt MA, Weiss RA. Receptor interference groups of 20 retroviruses plating on human cells. Virology 176(1), 58-69 (1990).
93. Sommerfelt MA, Williams BP, Clapham PR, Solomon E, Goodfellow PN, Weiss RA. Human T cell leukemia viruses use a receptor determined by human chromosome 17. Science (NY) 242(4885), 1557-1559 (1988).
94. Xie L, Green PL. Envelope is a major viral determinant of the distinct in vitro cellular transformation tropism of human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2. J. Virol. 79(23), 14536-14545 (2005).
95. Knight SC, Macatonia SE, Cruickshank K, Rudge P, Patterson S. Dendritic cells in HIV-1 and HTLV-1 infection. Adv. Exp. Med. Biol. 329, 545-549 (1993).
96. Macatonia SE, Cruickshank JK, Rudge P, Knight SC. Dendritic cells from patients with tropical spastic paraparesis are infected with HTLV-1 and stimulate autologous lymphocyte proliferation. AIDS research and human retroviruses 8(9), 1699-1706 (1992).
97. Hishizawa M, Imada K, Kitawaki T, Ueda M, Kadowaki N, Uchiyama T. Depletion and impaired interferon-a-producing capacity of blood plasmacytoid dendritic cells in human T-cell leukaemia virus type 1-infected individuals. Br. J. Haematol. 125(5), 568-575 (2004).
98. Azakami K, Sato T, Araya N et al. Severe loss of invariant NKT cells exhibiting anti-HTLV-1 activity in patients with HTLV-1-associated disorders. Blood 114(15), 3208-3215 (2009).
99. Geijtenbeek TB, Torensma R, Van Vliet SJ et al. Identifcation of DC-SIGN, a novel dendritic cell-specifc ICAM-3 receptor that supports primary immune responses. Cell 100(5), 575-585 (2000).
100. Wu L, Kewalramani VN. Dendritic-cell interactions with HIV: infection and viral dissemination. Nat. Rev. 6(11), 859-868 (2006).
101. Gummuluru S, Rogel M, Stamatatos L, Emerman M. Binding of human immunodefciency virus type 1 to immature dendritic cells can occur independently of DC-SIGN and mannose binding c-type lectin receptors via a cholesterol-dependent pathway. J. Virol. 77(23), 12865-12874 (2003).
102. Baribaud F, Pohlmann S, Leslie G, Mortari F, Doms RW. Quantitative expression and virus transmission ana lysis of DC-SIGN on monocyte-derived dendritic cells. J. Virol. 76(18), 9135-9142 (2002).
103. Burleigh L, Lozach PY, Schiffer C et al. Infection of dendritic cells (DCS), not DC-SIGN-mediated internalization of human immunodefciency virus, is required for long-term transfer of virus to Y cells. J. Virol. 80(6), 2949-2957 (2006).
104. Ceccaldi PE, Delebecque F, Prevost MC et al. DC-SIGN facilitates fusion of dendritic cells with human T-cell leukemia virus type 1-infected cells. J. Virol. 80(10), 4771-4780 (2006).
105. Jain P, Manuel SL, Khan ZK, Ahuja J, Quann K, Wigdahl B. DC-SIGN mediates cell-free infection and transmission of human T-cell lymphotropic virus type 1 by dendritic cells. J. Virol. 83(21), 10908-10921 (2009).
106. Kashima S, Rodrigues ES, Azevedo R et al. DC-SIGN (CD209) gene promoter polymorphisms in a brazilian population and their association with human T-cell lymphotropic virus type 1 infection. J. Gen. Virol. 90(Pt 4), 927-934 (2009).
107. Brody BA, Rhee SS, Sommerfelt MA, Hunter E. A viral protease-mediated cleavage of the transmembrane glycoprotein of mason-pfzer monkey virus can be suppressed by mutations within the matrix protein. Proc. Natl Acad. Sci. USA 89(8), 3443-3447 (1992).
108. Rein A, Mirro J, Haynes JG, Ernst SM, Nagashima K. Function of the cytoplasmic domain of a retroviral transmembrane protein: P15e-p2e cleavage activates the membrane fusion capability of the murine leukemia virus env protein. J. Virol. 68(3), 1773-1781 (1994).
109. Bobkova M, Stitz J, Engelstadter M, Cichutek K, Buchholz CJ. Identifcation of r-peptides in envelope proteins of c-type retroviruses. J. Gen. Virol. 83(Pt 9), 2241-2246 (2002).
110. Ilinskaya A, Heidecker G, Derse D. Opposing effects of a tyrosine-based sorting motif and a PDZ-binding motif regulate human T-lymphotropic virus type 1 envelope traffcking. J. Virol. 84(14), 6995-7004 (2010).
111. Kim FJ, Manel N, Boublik Y, Battini JL, Sitbon M Human T-cell leukemia virus type 1 envelope-mediated syncytium formation can be activated in resistant mammalian cell lines by a carboxy-terminal truncation of the envelope cytoplasmic domain. J. Virol. 77(2), 963-969 (2003).
112. Delamarre L, Pique C, Rosenberg AR et al. The Y-S-L-I tyrosine-based motif in the cytoplasmic domain of the human T-cell leukemia virus type 1 envelope is essential for cell-to-cell transmission. J. Virol. 73(11), 9659-9663 (1999).
113. Blot V, Delamarre L, Perugi F et al. Human DLG protein binds to the envelope glycoproteins of human T-cell leukemia virus type 1 and regulates envelope mediated cell-cell fusion in T lymphocytes. J. Cell Sci. 117(Pt 17), 3983-3993 (2004).
114. Pique C, Pham D, Tursz T, Dokhelar MC. The cytoplasmic domain of the human T-cell leukemia virus type I envelope can modulate envelope functions in a cell type-dependent manner. J. Virol. 67(1), 557-561 (1993).
115. Davis CG, Lehrman MA, Russell DW, Anderson RG, Brown MS, Goldstein JL. The JD mutation in familial hypercholesterolemia: Amino acid substitution in cytoplasmic domain impedes internalization of LDL receptors. Cell 45(1), 15-24 (1986).
116. Bonifacino JS, Traub LM. Signals for sorting of transmembrane proteins to endosomes and lysosomes. Ann. Rev. Biochem. 72, 395-447 (2003).
117. Dell'angelica EC, Mullins C, Bonifacino JS. Ap-4, a novel protein complex related to clathrin adaptors. J. Biol. Chem. 274(11), 7278-7285 (1999).
118. Janvier K, Bonifacino JS. Role of the endocytic machinery in the sorting of lysosome-associated membrane proteins. Mol. Biol. Cell 16(9), 4231-4242 (2005).
119. Traub LM, Kornfeld S, Ungewickell E. Different domains of the AP-1 adaptor complex are required for Golgi membrane binding and clathrin recruitment. J. Biol. Chem. 270(9), 4933-4942 (1995).
120. Dell'angelica EC, Klumperman J, Stoorvogel W, Bonifacino JS. Association of the AP-3 adaptor complex with clathrin. Science (NY) 280(5362), 431-434 (1998).
121. Ohno H, Aguilar RC, Yeh D, Taura D, Saito T, Bonifacino JS. The medium subunits of adaptor complexes recognize distinct but overlapping sets of tyrosine-based sorting signals. J. Biol. Chem. 273(40), 25915-25921 (1998).
122. Danis C, Deschambeault J, Do Carmo S, Cohen EA, Rassart E, Lemay G. The tyrosine-based yxxo targeting motif of murine leukemia virus envelope glycoprotein affects pathogenesis. Virology 324(1), 173-183 (2004).
123. Grange MP, Blot V, Delamarre L et al. Identifcation of two intracellular mechanisms leading to reduced expression of oncoretrovirus envelope glycoproteins at the cell surface. J. Virol. 74(24), 11734-11743 (2000).
124. Januszeski MM, Cannon PM, Chen D, Rozenberg Y, Anderson WF. Functional ana lysis of the cytoplasmic tail of moloney murine leukemia virus envelope protein. J. Virol. 71(5), 3613-3619 (1997).
125. Lodge R, Delamarre L, Lalonde JP et al. Two distinct oncornaviruses harbor an intracytoplasmic tyrosine-based basolateral targeting signal in their viral envelope glycoprotein. J. Virol. 71(7), 5696-5702 (1997).
126. Song C, Dubay SR, Hunter E. A tyrosine motif in the cytoplasmic domain of mason-Pfzer monkey virus is essential for the incorporation of glycoprotein into virions. J. Virol. 77(9), 5192-5200 (2003).
127. Sfakianos JN, Hunter E. M-PMV capsid transport is mediated by env/gag interactions at the pericentriolar recycling endosome. Traffc (Copenhagen, Denmark) 4(10), 671-680 (2003).
128. Berlioz-Torrent C, Shacklett BL, Erdtmann L et al. Interactions of the cytoplasmic domains of human and simian retroviral transmembrane proteins with components of the clathrin adaptor complexes modulate intracellular and cell surface expression of envelope glycoproteins. J. Virol. 73(2), 1350-1361 (1999).
129. Kennedy MB. Origin of PDZ (DHR, GLGF) domains. Trends Biochem. Sci. 20(9), 350 (1995).
130. Kim E, Sheng M. PDZ domain proteins of synapses. Nat. Rev. 5(10), 771-781 (2004).
131. Tonikian R, Zhang Y, Sazinsky Sl et al. A specifcity map for the PDZ domain family. PLoS biol. 6(9), e239 (2008).
132. Van Ham M, Hendriks W. PDZ domains-glue and guide. Mol. Biol. Rept. 30(2), 69-82 (2003).
133. Sheng M, Sala C. PDZ domains and the organization of supramolecular complexes. Ann. Rev. Neuro. 24, 1-29 (2001).
134. Xavier R, Seed B. PDZ domains and the politics of polarity in lymphocytes. Immunity 22(6), 655-656 (2005).
135. Haucke V. Cargo takes control of endocytosis. Cell 127(1), 35-37 (2006).
136. Puthenveedu Ma, Von Zastrow M: Cargo regulates clathrin-coated pit dynamics. Cell 127(1), 113-124 (2006).
137. Trejo J. Internal pdz ligands: Novel endocytic recycling motifs for G protein-coupled receptors. Mol. Pharmacol. 67(5), 1388-1390 (2005).
138. Wolfe BL, Trejo J. Clathrin-dependent mechanisms of G protein-coupled receptor endocytosis. Traffc (Copenhagen, Denmark) 8(5), 462-470 (2007).
139. Ochsenbauer C, Dubay SR, Hunter E. The rous sarcoma virus env glycoprotein contains a highly conserved motif homologous to tyrosine-based endocytosis signals and displays an unusual internalization phenotype. Mol. Cell. Biol. 20(1), 249-260 (2000).
140. Traub LM. Tickets to ride: selecting cargo for clathrin-regulated internalization. Nat/ Rev. 10(9), 583-596 (2009).
141. Yamanaka T, Ohno S. Role of lgl/dlg/scribble in the regulation of epithelial junction, polarity and growth. Front Biosci. 13, 6693-6707 (2008).
142. Yoshida S, Higuchi M, Shoji T et al. Knockdown of synapse-associated protein dlg1 reduces syncytium formation induced by human T-cell leukemia virus type 1. Virus genes 37(1), 9-15 (2008).
143. Barre-Sinoussi F, Chermann JC, Rey F et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune defciency syndrome (aids). Science (NY) 220(4599), 868-871 (1983).
144. Tsukasaki K, Hermine O, Bazarbachi A et al. Defnition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J. Clin. Oncol. 27(3), 453-459 (2009).
145. Goncalves DU, Proietti FA, Ribas JG et al. Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases. Clin. Microbiol. Rev. 23(3), 577-589 (2010).
146. Mitchell MS, Bodine ET, Hill S et al. Phenotypic and genotypic comparisons of human T-cell leukemia virus type 1 reverse transcriptases from infected T-cell lines and patient samples. J. Virol. 81(9), 4422-4428 (2007).
147. Ina Y, Gojobori T. Molecular evolution of human T-cell leukemia virus. J. Mol. Evol. 31(6), 493-499 (1990).
148. Niewiesk S, Daenke S, Parker Ce et al. The transactivator gene of human T-cell leukemia virus type I is more variable within and between healthy carriers than patients with tropical spastic paraparesis. J. Virol. 68(10), 6778-6781 (1994).
149. Miura T, Fukunaga T, Igarashi T et al. Phylogenetic subtypes of human T-lymphotropic virus type I and their relations to the anthropological background. Proc. Natl Acad. Sci. USA 91(3), 1124-1127 (1994).
150. Overbaugh J, Bangham CR. Selection forces and constraints on retroviral sequence variation. Science (NY) 292(5519), 1106-1109 (2001).
151. Baba E, Nakamura M, Ohkuma K et al. A peptide-based human T cell leukemia virus type 1 vaccine containing T and B cell epitopes that induces high titers of neutralizing antibodies. J. Immunol. 154(1), 399-412 (1995).
152. Kozako T, Fukada K, Hirata S et al. Effcient induction of human T-cell leukemia virus-1-specifc CTL by chimeric particle without adjuvant as a prophylactic for adult T-cell leukemia. Mol. Immunol. 47(2-3), 606-613 (2009).
153. Lynch MP, Kaumaya P T. Advances in HTLV-1 peptide vaccines and therapeutics. Curr. Prot. Pept. Sci. 7(2), 137-145 (2006).
154. Kchour G, Makhoul NJ, Mahmoudi M et al. Zidovudine and interferon-a treatment induces a high response rate and reduces HTLV-1 proviral load and VEGF plasma levels in patients with adult T-cell leukemia from north east Iran. Leukemia & lymphoma 48(2), 330-336 (2007).
155. Pinon JD, Kelly SM, Price NC, Flanagan JU, Brighty DW. An antiviral peptide targets a coiled-coil domain of the human T-cell leukemia virus envelope glycoprotein. J. Virol. 77(5), 3281-3290 (2003).
156. Lamb D, Schuttelkopf AW, Van Aalten DM, Brighty DW. Highly specifc inhibition of leukaemia virus membrane fusion by interaction of peptide antagonists with a conserved region of the coiled coil of envelope. Retrovirology 5, 70 (2008).
157. Sagara Y, Inoue Y, Shiraki H, Jinno A, Hoshino H, Maeda Y. Identifcation and mapping of functional domains on human T-cell lymphotropic virus type 1 envelope proteins by using synthetic peptides. J. Virol. 70(3), 1564-1569 (1996).
158. Mirsaliotis A, Nurkiyanova K, Lamb D, Kuo C W, Brighty DW. Resistance to neutralization by antibodies targeting the coiled coil of fusion-active envelope is a common feature of retroviruses. J. Biol. Chem. 282(50), 36724-36735 (2007).
159. Romer D, Brighty DW, Robson CL, Sattentau QJ. Candidate polyanionic microbicides inhibit human T-cell lymphotropic virus type 1 receptor interactions, cell-free infection, and cell-cell spread. Antimicrob. Agents Chemother. 53(2), 678-687 (2009).
160. Cianciolo Gj, Copeland TD, Oroszlan S, Snyderman R. Inhibition of lymphocyte proliferation by a synthetic peptide homologous to retroviral envelope proteins. Science, NY 230(4724), 453-455 (1985).
161. Blaise S, Mangeney M, Heidmann T. The envelope of mason-pfzer monkey virus has immunosuppressive properties. J. Gen. Virol. 82(Pt 7), 1597-1600 (2001).
162. Mangeney M, Renard M, Schlecht-Louf G et al. Placental syncytins: Genetic disjunction between the fusogenic and immunosuppressive activity of retroviral envelope proteins. Proc. Natl Acad. Sci. USA 104(51), 20534-20539 (2007).
163. Schlecht-Louf G, Renard M, Mangeney M et al. Retroviral infection in vivo requires an immune escape virulence factor encrypted in the envelope protein of oncoretroviruses. Proc Natl Acad. Sci. USA 107(8), 3782-3787 (2010).